Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Deffered Revenue (2016 - 2025)

Intellia Therapeutics has reported Non-Current Deffered Revenue over the past 11 years, most recently at $12.5 million for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 44.53% to $12.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Sep 2025, down 44.53% year-over-year, with the annual reading at $18.3 million for FY2024, 53.01% down from the prior year.
  • Non-Current Deffered Revenue was $12.5 million for Q3 2025 at Intellia Therapeutics, roughly flat from $12.5 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $63.5 million in Q4 2021 and troughed at $12.5 million in Q2 2025.
  • The 5-year median for Non-Current Deffered Revenue is $25.7 million (2022), against an average of $29.6 million.
  • Year-over-year, Non-Current Deffered Revenue surged 251.99% in 2021 and then crashed 71.99% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $63.5 million in 2021, then crashed by 68.6% to $19.9 million in 2022, then surged by 94.93% to $38.9 million in 2023, then tumbled by 53.01% to $18.3 million in 2024, then crashed by 31.32% to $12.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Non-Current Deffered Revenue are $12.5 million (Q3 2025), $12.5 million (Q2 2025), and $13.2 million (Q1 2025).